Imaging biomarkers play a wide-ranging role in clinical trials for neurological disorders. This
includes selecting the appropriate trial participants, establishing target engagement and …

Introduction While the imaging signatures of frontotemporal lobar degeneration (FTLD)
phenotypes and genotypes are well-characterized based on group-level descriptive …

Background There has been increasing interest in cortical microstructure as a
complementary and earlier measure of neurodegeneration than macrostructural atrophy, but …

The aim of this research was to test a novel in‐vivo brain MRI analysis method that could be
used in clinical cohorts to investigate cortical architecture changes in patients with …

Objective To investigate cortical microstructural measures from diffusion MRI as
“neurodegeneration” markers that could improve prognostic accuracy in mild cognitive …

Characterizing a particular neurodegenerative condition against others possible diseases
remains a challenge along clinical, biomarker, and neuroscientific levels. This is the …

Background Alzheimer's disease (AD) neuropathology reveals progressive microstructural
alterations of cortical architecture. Recent studies reported intriguing biphasic trajectories of …

Background Frontotemporal dementias (FTD) include a genetically heterogeneous group of
conditions with distinctive molecular, radiological and clinical features. The majority of …

Phenotypic and genetic relationships between white matter microstructure (ie, fractional
anisotropy [FA]) and peripheral inflammatory responses (ie, circulating cytokines) have …

Background Frontotemporal lobar degeneration (FTLD) is a neuropathological construct
with multiple clinical presentations, including the behavioural variant of frontotemporal …